Skip to main content
PULM
NASDAQ Life Sciences

Strategic Investor Discloses 9.99% Stake, Provides Interim Financing for Eos SENOLYTIX Merger

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$1.42
Mkt Cap
$5.113M
52W Low
$1.16
52W High
$9.37
Market data snapshot near publication time

summarizeSummary

RCM Eos PIPE HOLDINGS, LLC, an affiliate of Eos SENOLYTIX, Inc., has disclosed a 9.99% beneficial ownership stake in Pulmatrix, Inc. through a $1 million private placement of convertible preferred stock, providing crucial interim financing ahead of their planned merger.


check_boxKey Events

  • Strategic Investment Disclosed

    RCM Eos PIPE HOLDINGS, LLC, managed by Kevin M. Slawin (CEO of Eos SENOLYTIX, Inc.), reported a 9.99% beneficial ownership stake in Pulmatrix, Inc.

  • $1 Million Interim Financing

    The stake was acquired through a $1 million private placement of Series B Convertible Preferred Stock, providing critical capital for Pulmatrix.

  • Merger Support Confirmed

    The investment is explicitly tied to the upcoming merger with Eos SENOLYTIX, Inc., with the investor agreeing to vote in favor of the transaction.

  • Conversion Terms Detailed

    The preferred stock is convertible into common stock at a price of $2.20 per share, subject to a 9.99% beneficial ownership blocker.


auto_awesomeAnalysis

This Schedule 13D filing reveals a significant strategic investment by RCM Eos PIPE HOLDINGS, LLC, an entity controlled by Kevin M. Slawin, who is also the CEO of Eos SENOLYTIX, Inc. The $1 million investment in Series B Convertible Preferred Stock, representing a substantial portion of Pulmatrix's market cap, provides essential interim financing for Pulmatrix prior to its merger with Eos SENOLYTIX. The investor's commitment to vote in favor of the merger, coupled with the conversion price of $2.20 per share (above the current stock price), signals strong confidence in the combined entity and its strategic direction. This financing helps secure the company's runway and de-risks the merger process.

At the time of this filing, PULM was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $1.16 to $9.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PULM - Latest Insights

PULM
Apr 22, 2026, 4:26 PM EDT
Source: Wiseek News
Importance Score:
9
PULM
Apr 22, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
PULM
Apr 21, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
PULM
Apr 21, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
PULM
Mar 27, 2026, 5:16 PM EDT
Filing Type: 8-K
Importance Score:
10
PULM
Mar 26, 2026, 9:11 AM EDT
Filing Type: 425
Importance Score:
10
PULM
Mar 02, 2026, 8:05 AM EST
Source: Dow Jones Newswires
Importance Score:
8
PULM
Mar 02, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
PULM
Mar 02, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
8
PULM
Feb 26, 2026, 8:20 AM EST
Filing Type: 10-K
Importance Score:
9